AVASTINĀ® First Line in Metastatic Renal Cancer
AVASTINĀ® First Line in Metastatic Renal Cancer
This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.
Inclusion Criteria:
Exclusion Criteria:
-